A kind of hpv gene chip and its preparation method and application

Abstract

The invention discloses an HPV gene chip, which can accurately detect, screen and type one or more HPV subtypes individually or simultaneously, and monitor the human genome beta globin and HPV primer amplification quality control points In the whole detection process, the HPV gene chip can have high sensitivity and specificity; the invention also discloses the preparation method of the HPV gene chip, using PCR reverse dot hybridization method to screen specificity probes, through the HPV gene chip The optimization of spotting probe concentration improves the quality and efficiency of hybridization, and the gene chip with optimized conditions is further verified with clinical samples. The HPV gene chip of the invention has good clinical application prospect.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an HPV gene chip and its preparation method and application. Background technique [0002] Cervical cancer is one of the most common malignant tumors in women, and its incidence rate accounts for the fourth among female tumors in the world. According to statistics in recent years, cervical cancer patients in my country are getting younger and younger, and their morbidity and mortality are still at a high level. Therefore, early screening of cervical precancerous lesions has a great effect on the prevention of cervical cancer. , which has caused researchers to attach great importance to early screening of cervical cancer. In 1983, German scientist Hausen put forward the theory that HPV is the cause of cervical cancer. Since then, many domestic and foreign researchers have done a lot of research on the relationship between cervical cancer and HPV infection, and have made a lot ...

AI Technical Summary

Problems solved by technology

Fluorescence in situ hybridization can locate and have a low false positive rate, but its detection sensitivity is low, the operation is cumbersome, time-consuming and labor-intensive, and it is not suitable for the screening of large-throughput clinical samples

In 1999, hybrid capture second-generation technology (HCⅡ) was approved for HPV detection. This technology was launched by Digene Corporation of the United States. It was the first to be approved by the U.S. Food and Drug Administration (FDA) and is the most widely used HPV detection technology in the world. Although HCⅡ detection is specific Good sex and high sensitivity, but HCⅡ cannot be tested for typing, high cost, and has no internal quality control and other defects

In 2011, the US FDA approved the first-line primary screening of Cobas 4800HPV technology, which can qualitatively detect 14 high-risk types of HPV, and has β-globin as an internal quality control, but its detection of HPV types is limited to these 14 high-risk types

In recent years, there are still some shortcomings in the clinical application of HPV detection methods, such as the inability to detect multiple subtypes of HPV at one time, the operation process is cumbersome, the detection cost is high, and it is time-consuming and labor-intensive.

Images